» Great interest in Dicots LIB-01
» Promore makes reverse acquisition and shifts operations
» Xintela makes new progress
» Chordate installs in Germany and launches in the United Arab Emirates
» CAR T deal puts focus on Elicera's technology
Read BioStock's weekly newsletter for v.47 here.
Morning news
CLS begins cooperation with Quest International around aftermarket service and logistics to support further expansion. Read more.
Calliditas Therapeutics initiates clinical study to evaluate setanaxib for Alport syndrome. Read more.
Today the subscription period begins in Annexin Pharmaceuticals rights issue. Read more.
SyntheticMR announces that they have expanded their partnership with Philips to include SyMRI 3D. Read more.
The board of directors Fluicell proposes a rights issue of units of approximately SEK 30 million. Read more.
Zealand Pharma appoints Enrique Conterno and Elaine Sullivan to board observers. Read more.
Lipum changes liquidity provider to Carnegie Investment Bank. Read more.
Scandinavian ChemoTechs IR consultant leaves management. Read more.
lundbeck is hosting an R&D event in London today. Read more.
Revenue is organizing a capital markets day today. Read more.
Reports
AcuCort BrainCool Diamyd Medical Duearity Elekta Fluicell Saniona Xbrane Biopharma
Notices of meetings
Communiqués
Nomination committees
Insider trading
BBS-Bioactive Bone Substitutes
Changes in the number of shares and votes
Ascelia Pharma Elos Medtech Medicover Sobi
Change of certified advisor
Biosergen Elicera Therapeutics Ellen Genovese Iconovo Integral Lipidor Nanexa Prostatype Genomics Redwood Pharma ScandiDos Surgical Science
News since Wednesday lunch
Gubra announced that the first participant has been dosed in a phase I study with amylin agonist (GUBamy) for the treatment of obesity. Read more.
Observe Medical has received its first order from Slovakia. Read more.
QuiaPEG announced the registration and allocation of the previously communicated directed set-off issue. Read more.
Orthoma Approximately SEK 27,2 million was added through the exercise of warrants of series TO 2B. Read more.
ScandiDos has received MDR certification for Delta4 Phantom+ products. Read more.
Senior executives and board members have subscribed for shares in Active Biotechs ongoing rights issue. Read more.
Scandinavian ChemoTech updated on its main milestone. Read more.
SenzaGen announced that it is changing liquidity guarantor to Carnegie. Read more.
Stenocare updated applicable conditions for TO1 and TO2. Read more.
BergenBio announced an update regarding the company's share issue. Read more.
CS MEDICA has postponed the publication of its annual report until February 24, 2024. Read more.
Pila Pharmas The issue runs until December 4th. Read more.
This morning's price development
Winner: Ectin +40,5%, QuiaPEG +23,5%, BioWorks Technologies 18,5%, Asarina Pharma +13,3%, Medimi +12,9%
Förlorare: Fluicell -56,7%, Xbrane Biopharma -26,0%, Promore Pharma -18,6%, Medivir -15,4%, BrainCool -12,6%
Index: OMXS30 2235 +0,13%, Healthcare -0,67%
More from BioStock
» Biovica CEO: "DiviTum TKa has had a good start in the US"
» Curasights CEO: “Working on accelerated plan for uTREAT”
» Cyxone's CEO on the issue: "this round will take us into early 2025"
» Prolight's CEO: "Proof-of-Performance in thoroughbreds important milestone"
» Ziccum has secured agreements in all three market segments